DGX · NYSE · Medical - Diagnostics & Research

Quest Diagnostics

Provides clinical testing, pathology, and laboratory services through a North American network.

$244.50
After-hours close+1.68 (+0.69%)
At close$242.82(−0.73%)

Breakdown13F · Form 4

Institutions 129.18%Insiders 0.44%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 110.37M · Float 109.84M · 99.5% free float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
BlackRock, Inc.9.28M8.40%13FAug 7, 2026
Vanguard Capital Management LLC7.23M6.55%13FAug 13, 2026
T. Rowe Price Associates, Inc.7.21M6.50%13GAug 14, 2025
Vanguard Portfolio Management LLC6.13M5.55%13FAug 13, 2026
State Street Corp5.52M5.00%13FAug 7, 2026

Institutions13F, as of Jun 30, 2026

1,121 holders · 142.57M shares · 119 new positions · 550 increased · 350 reduced · 82 closed

HolderShares% outstandingChg q/qFiled
BlackRock, Inc.9.28M8.40%+103.1KAug 7, 2026
Vanguard Capital Management LLC7.23M6.55%+87.7KAug 13, 2026
Vanguard Portfolio Management LLC6.13M5.55%+49.6KAug 13, 2026
State Street Corp5.52M5.00%+135.8KAug 7, 2026
Price T Rowe Associates Inc /MD/5.44M4.93%−853.0KAug 14, 2026
Boston Partners4.74M4.30%+732.2KAug 4, 2026
JPMorgan Chase & Co3.52M3.19%−326.0KAug 12, 2026
Geode Capital Management, LLC3.14M2.84%+51.6KAug 12, 2026

Beneficial owners13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
BlackRock, Inc.8.40%9.31M13GApr 17, 2025
Vanguard Capital Management7.53%8.27M13GApr 30, 2026
T. Rowe Price Associates, Inc.6.50%7.21M13GAug 14, 2025
Vanguard Portfolio Management5.54%6.10M13GApr 29, 2026

InsidersForm 4

InsiderRoleShares% outstandingFiled
J. E. Davisdirector, officer: CEO and President132.4K0.12%Jun 2, 2026
Catherine T. Dohertyofficer: EVP, Regional Businesses67.1K0.06%Mar 6, 2026
Michael E. Prevoznikofficer: SVP & General Counsel37.6K0.03%Mar 6, 2026
Michael J. Deppeofficer: SVP, Corp. Controller & CAO35.2K0.03%Mar 6, 2026
Sam Samadofficer: Executive Vice President & CFO33.5K0.03%Jul 27, 2026
Timothy M. Ringdirector31.1K0.03%May 21, 2026
Gary M. Pfeifferdirector31.0K0.03%May 21, 2026
Timothy L. Maindirector22.5K0.02%Jul 27, 2026
Vicky B. Greggdirector18.4K0.02%Jul 27, 2026
Patrick Plewmanofficer: SVP for Diagnostic Services15.3K0.01%Jul 27, 2026

29 people have not refiled in the last 18 months (1.77M shares), so they are not in the figure above

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Jul 28, 2026
Mark E. Delaneyofficer: SVP & Chief Commercial Officer
Sale1,600$235.1810,335
Jun 4, 2026
Karthik Kuppusamyofficer: SVP, Clinical Solutions
Sale8,147$200.0013,510
Jun 1, 2026
J. E. Davisdirector, officer: CEO and President
Sale10,000$194.14132,423
Mar 4, 2026
Karthik Kuppusamyofficer: SVP, Clinical Solutions
Sale2,628$204.8613,441
Mar 5, 2026
Patrick Plewmanofficer: SVP for Diagnostic Services
Sale2,855$206.2115,198
Mar 5, 2026
Michael E. Prevoznikofficer: SVP & General Counsel
Sale3,878$206.2137,557
Mar 5, 2026
Catherine T. Dohertyofficer: EVP, Regional Businesses
Sale5,558$206.2167,122
Mar 3, 2026
Patrick Plewmanofficer: SVP for Diagnostic Services
Sale410$207.7315,198
Mar 2, 2026
J. E. Davisdirector, officer: CEO and President
Sale10,000$212.52117,185
Mar 3, 2026
Michael E. Prevoznikofficer: SVP & General Counsel
Sale526$207.7337,557

CongressHouse and Senate disclosures

MemberTypeAmountOwnerTradedDisclosed
Rep. Carol Devine Miller · WV01Sale$15,001 – $50,000SpouseMar 10, 2025Aug 14, 2026
Rep. Julie Johnson · TX32Sale$1,001 – $15,000JointOct 30, 2025Aug 6, 2026
Sen. Alan ArmstrongPurchase$1,001 – $15,000JointMar 27, 2026Jul 21, 2026